Don’t Cut Coverage for Proven Obesity Treatments

Lawmaker Letter:

As your constituent, I urge you to maintain coverage for FDA-approved obesity medications like GLP-1 therapies in Washington’s Medicaid program.

Eliminating this coverage would not only limit access to proven, preventive care—it would also drive up long-term healthcare spending. Obesity-related complications lead to costly emergency interventions and decreased workplace productivity, costing Washington employers an estimated $500 per employee each year.

Investing in treatment now is both good healthcare policy and smart fiscal management. Please stand with Washington families and oppose any cuts that would remove access to these essential medications.